Profile data is unavailable for this security.
About the company
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.
- Revenue in CNY (TTM)10.92bn
- Net income in CNY1.60bn
- Incorporated1997
- Employees12.27k
- LocationChina Resources Double-Crane Pharmaceutical Co LtdNo.1 Lize East Er RoadWangjing, Chaoyang DistrictBEIJING 100102ChinaCHN
- Phone+86 1 064398099
- Fax+86 1 064398086
- Websitehttps://www.dcpc.com/
Mergers & acquisitions
Acquired company | 600062:SHH since announced | Transaction value |
---|---|---|
China Resources Zizhu Pharmaceutical Co Ltd | 15.14% | 433.04m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Joincare Pharmaceutical Group Ind. Co. | 16.16bn | 1.40bn | 21.37bn | 14.37k | 14.95 | 1.49 | -- | 1.32 | 0.7626 | 0.7626 | 8.76 | 7.64 | 0.4444 | 2.29 | 5.29 | 1,125,043.00 | 8.03 | 8.46 | 16.91 | 18.84 | 61.38 | 62.72 | 18.07 | 17.00 | 1.89 | -- | 0.2222 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.77bn | -408.93m | 23.25bn | 1.45k | -- | 3.83 | -- | 6.17 | -0.3139 | -0.3139 | 2.38 | 3.76 | 0.3611 | 0.476 | 3.69 | 2,598,424.00 | -3.92 | 8.97 | -5.65 | 13.15 | 41.80 | 45.59 | -10.85 | 20.12 | 1.19 | -3.44 | 0.3076 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
Tasly Pharmaceutical Group Co Ltd | 8.65bn | 1.03bn | 23.46bn | 9.22k | 22.98 | 1.87 | -- | 2.71 | 0.6833 | 0.6833 | 5.77 | 8.39 | 0.4973 | 1.68 | 10.87 | 938,279.60 | 5.65 | 5.47 | 6.96 | 7.25 | 65.99 | 48.42 | 11.36 | 8.94 | 2.40 | 4.60 | 0.2259 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
China Resources Dubl-Crne Phrmctl Co Ltd | 10.92bn | 1.60bn | 24.28bn | 12.27k | 14.96 | 2.41 | -- | 2.22 | 1.56 | 1.56 | 10.65 | 9.67 | 0.6991 | 2.82 | 5.58 | 889,809.70 | 10.21 | 8.40 | 14.77 | 11.08 | 55.29 | 58.19 | 14.60 | 11.98 | 1.14 | -- | 0.0247 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
Kangmei Pharmaceutical Co Ltd | 4.97bn | 244.14m | 26.62bn | 4.41k | 108.54 | 3.77 | -- | 5.35 | 0.0177 | 0.0177 | 0.3596 | 0.5095 | 0.3447 | 1.39 | 2.50 | 1,127,547.00 | 1.71 | -17.60 | 2.59 | -32.24 | 21.52 | -72.78 | 4.96 | -101.19 | 0.8735 | -- | 0.1544 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
Hubei Jumpcan Pharmaceutical Co Ltd | 9.06bn | 2.82bn | 27.43bn | 5.23k | 9.69 | 2.03 | -- | 3.03 | 3.07 | 3.07 | 9.85 | 14.65 | 0.5262 | 3.09 | 4.60 | 1,732,306.00 | 16.41 | 16.23 | 21.92 | 20.88 | 79.06 | 82.64 | 31.20 | 24.42 | 3.13 | -- | 0.116 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.14bn | 1.01bn | 28.75bn | 8.22k | 28.02 | 3.27 | -- | 3.14 | 0.6995 | 0.6995 | 6.32 | 6.00 | 0.4681 | 1.09 | 3.23 | 1,112,139.00 | 5.16 | 5.67 | 7.35 | 8.07 | 60.27 | 60.52 | 11.03 | 11.61 | 0.8547 | 5.52 | 0.4506 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
Holder | Shares | % Held |
---|---|---|
E Fund Management Co., Ltd.as of 31 Dec 2023 | 25.54m | 2.49% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 8.89m | 0.87% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 8.24m | 0.81% |
CITIC Securities Co., Ltd. (Invt Port)as of 30 Sep 2023 | 5.79m | 0.57% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 4.70m | 0.46% |
Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 4.17m | 0.41% |
Cinda Fund Management Co. Ltd.as of 31 Dec 2023 | 3.78m | 0.37% |
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 3.59m | 0.35% |
HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 3.44m | 0.34% |
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 3.17m | 0.31% |